Kalray Unveils Coolidge™ at CES 2020
6.1.2020 20:00:00 EET | Business Wire | Press release
Kalray (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced the company will showcase its MPPA-3 aka Coolidge™, its third generation of unique and patented MPPA® (Massively Parallel Processor Array) processor family at CES 2020 in Las Vegas, from January 7 to 10, 2020.
COOLIDGE™ DEMONSTRATED AT CES
Just a few weeks after having received the first samples of Coolidge from manufacturing, Kalray will showcase a complete Artificial Intelligence use case running on Coolidge at CES, including a common demo with NXP, one of the leading semiconductor companies.
Coolidge samples general availability is planned for April.
COOLIDGE UNIQUELY POSITIONED FOR THE BOOMING MARKET OF INTELLIGENT SYSTEMS
Coolidge represents a 25X performance improvement (1) over second generation MPPA, with improvement of artificial intelligence capacities, increased ease of programming and higher-performance interfaces in particular for next generation of data centers.
Coolidge is targeting the booming market of intelligent systems, from next generation of data center infrastructure, 5G to next generation of cars. Coolidge is a compelling choice versus FPGA, which are expensive and difficult to program; GPU, which are tailored for mathematical algorithms; and AI processors, designed for AI only. Coolidge-based cards can be configured to deliver specialized acceleration performance in a wide set of demanding functions such as vision, signal processing, encryption, software stacks, real-time protocols, etc.
Eric Baissus, CEO of Kalray comments: “Yet another important phase for the company. Coolidge is the platform to support company's ambitions on data center markets, answering needs of growing diversity of Data Center workload acceleration and on automotive, enabling integration of multiple critical functions on the same chip while providing huge computing performance.”
DATA CENTER’S GROWING NEED FOR ACCELERATIONS AT COMPUTE, STORAGE AND NETWORKING
“2CRSi is eager to evaluate the new Coolidge processor from Kalray and excited to explore solutions leveraging Kalray’s configurable cards. The performance of this third-generation processor will enable an expansion of our offer in high-growth areas such as Artificial Intelligence or compute acceleration, while enabling more and more distributed and disaggregated data center implementations”, said Alain Wilmouth, CEO of 2CRSi.
AUTOMOTIVE AND EMBEDDED MARKETS NEED FOR INTEGRATION OF MULTIPLE CRITICAL FUNCTIONS AND HIGH COMPUTE PERFORMANCE
“We are very happy to see the strategic partnership with Kalray reach a new milestone and have Coolidge integrated into the NXP BlueBox, our development platform for automated driving, showcased at CES. We are convinced NXP and Kalray will bring multiple benefits to the development and industrialization of ADAS and AD vehicles with safe and secure solutions integrating multiple critical functions and providing very high computing performance” said Kamal Khouri, Vice President & General Manager, Advanced Driver Assistance, NXP.
Coolidge has been designed to address the challenges and constraints of the new generation of intelligent systems:
- High computing power with low energy consumption
- Open and easily programmable system
- Real-Time data processing and deterministic behavior
- Concurrent execution of many heterogeneous critical tasks in parallel on a single chip
- Advanced security and safety mechanisms suitable for the most demanding systems, defined in collaboration with Kalray’s partners in the aerospace, defense and automotive fields
For more information and to view the demonstrations, come and visit us at CES from January 7 to 10 at Las Vegas, USA: NXP’s booth #CP18, Central Plaza.
Next publication:
January 22, 2020: H2 2019 business report
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is the pioneer in processors for new intelligent systems. A genuine technological breakthrough, “intelligent” processors are able to intelligently analyze a vast quantity of data on the fly and to make decisions and interact in real time with the outside world. These intelligent processors will be largely deployed in fast-growing sectors such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as in healthcare equipment, drones and robots. Kalray’s offering spans both processors and global solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l’Énergie Atomique”, the French Alternative Energies and Atomic Energy Commission), Kalray addresses a broad spectrum of customers including server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Read more at: www.kalrayinc.com
1 25 TOPS (Tera Operations Per Second) performance for Coolidge versus 1 TOPS for previous generation Bostan
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005664/en/
Contact information
INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalray.eu
Tel.
+33 (0)4 76 18 90 71
ACTUS finance & communication
Caroline LESAGE
kalray@actus.fr
+
33 1 53 67 36 79
MEDIA CONTACTS
Loic HAMON
communication@kalray.eu
Tel.
+33 (0)4 76 18 90 71
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel.
+33 (0)4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
